Intellikine, Inc. and the PKD Foundation Collaborate to Advance Next-Generation Therapies for Polycystic Kidney Disease

Published: Feb 10, 2011

LA JOLLA, Calif.--(BUSINESS WIRE)--Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the PKD Foundation today announced a collaboration to investigate novel, orally-available small molecule kinase inhibitors of the TORC1 and TORC2 complexes as a potential treatment for patients with polycystic kidney disease (PKD).

Back to news